Alector, Inc. announced that it will discontinue its Phase 2 PROGRESS‑AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease. The decision follows a pre‑specified futility analysis conducted by an independent data monitoring committee, which concluded the study was unlikely to meet its primary endpoint of slowing disease progression.
The IDMC’s analysis indicated that the trial’s interim data did not show a clinically meaningful difference in the primary endpoint, and the probability of success in the remaining enrollment was judged too low to justify continued investment. The company’s statement emphasized that the discontinuation is disappointing for patients, caregivers, investigators and study staff, but it will continue to advance its broader pipeline of ABC‑enabled candidates.
The trial was the only clinical‑stage asset in Alector’s partnership with GSK. Both nivisnebart and the earlier GSK‑partnered program latozinemab failed key clinical milestones, meaning that the $700 million upfront payment and potential $1.5 billion in milestone payments are unlikely to be realized. The loss of this partnership removes a significant potential revenue engine and further limits the company’s near‑term financial options.
Alector remains focused on its proprietary Alector Brain Carrier (ABC) platform and its pipeline of wholly owned candidates. The company plans to submit IND applications for its anti‑amyloid antibody AL037/AL137 and its glucocerebrosidase enzyme replacement therapy AL050 in late 2026 or 2027, and it continues to develop several siRNA programs. The company’s cash balance of $256 million, as of December 31 2025, is expected to fund operations through 2027, but the absence of approved products and the recent setbacks increase the urgency of advancing these assets.
Financially, Alector reported a net loss of $37.3 million ($0.34 per share) for the quarter ended December 31 2025, compared with a net loss of $2.1 million ($0.02 per share) for the same period in 2024. Collaboration revenue for the quarter was $6.2 million. The company’s cash runway is therefore more constrained, and the discontinuation of the GSK partnership further tightens its financial outlook.
Management said, “This outcome is disappointing for patients and families affected by Alzheimer’s disease and underscores the complexity of developing effective treatments for this devastating disease.” CEO Arnon Rosenthal added, “We are deeply grateful to the patients, caregivers, investigators and study staff who participated in the PROGRESS‑AD trial and contributed to advancing the scientific understanding of progranulin biology in neurodegeneration. We remain committed to progressing our broader pipeline of programs targeting neurodegenerative disease, including multiple wholly owned candidates enabled by our ABC platform.”
The announcement was met with a negative market reaction, reflecting concerns about the company’s pipeline and the loss of its partnership with GSK. Analysts noted that the failure of both nivisnebart and latozinemab raises doubts about the viability of targeting progranulin and underscores the challenges of developing treatments for neurodegenerative diseases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.